J. Goldman & Co’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

J. Goldman & Co’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Buy	+16,200	New	+$949K	0.03%	442

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.28% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

J. Goldman & Co's XPH Position: Q2 2022 in Review

J. Goldman & Co sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2022, closing a stake of 6,557 shares — an estimated $297K sold.

J. Goldman & Co first reported a position in XPH in Q1 2022 and held it in 1 quarter. The position peaked at $297K in Q1 2022. 71 funds tracked by Wall St. Rank hold XPH as of Q2 2022.

J. Goldman & Co reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 6,557 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2022, an estimated $297K.
J. Goldman & Co first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2022 and held it in 1 quarter.
J. Goldman & Co's State Street SPDR S&P Pharmaceuticals ETF position peaked at $297K in Q1 2022.
71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.